Porphyrin photosensitizers including 5,15-di(naphthalimide) moieties useful for photocatalytic hydrogen evolution, compositions including the same, and methods of use thereof.

The invention relates to metal complex compounds of the formula M.sub.k(L).sub.x(Y).sub.kz-nx, where the ligand L has the formula (I), and to metal complex compounds which include the reaction product of at least one salt or a complex of a transition metal or a main group metal element of the groups 13 to 15 and at least one 1,3-ketoamide. Such complex compounds are suitable in particular as catalysts for polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such metal complex compound as the catalyst. The invention additionally relates to different uses of the two-component polyurethane compositions.

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid-conjugated platinum compounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

Pt.sub.2M heterotrinuclear metal-organic alkynyl complexes have a structure of formula (I): [Pt.sub.2M(μ-PR.sub.2CH.sub.2PRCH.sub.2PR.sub.2).sub.2(C≡CR′).sub.2(C≡CR″).sub.2].sup.+.sub.mA.sup.m−. In formula (I), μ represents a bridging ligand; PR.sub.2CH.sub.2PRCH.sub.2PR.sub.2 is a type of tridentate phosphine ligands; the subscript number of each letter represents the number of each group. The complexes present phosphorescent emission, and the color distribution of the emitted light is relatively broad from blue-green to orange-red. The complexes can be used as photoluminescent materials in the fields of displays, lighting, sensors and biomarkers. Among the complexes, Cu complexes also exhibit reversible self-recovery photochromic performance. Under UV irradiation, the complexes change from a colorless or light color state to a dark color state rapidly, and after stopping UV irradiation, they gradually return to the light color state.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and/or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

Pt.sub.2M heterotrinuclear metal-organic alkynyl complexes have a structure of formula (I): [Pt.sub.2M(-PR.sub.2CH.sub.2PRCH.sub.2PR.sub.2).sub.2(CCR).sub.2(CCR).sub.2].sup.+.sub.mA.sup.m. In formula (I), represents a bridging ligand; PR.sub.2CH.sub.2PRCH.sub.2PR.sub.2 is a type of tridentate phosphine ligands; the subscript number of each letter represents the number of each group. The complexes present phosphorescent emission, and the color distribution of the emitted light is relatively broad from blue-green to orange-red. The complexes can be used as photoluminescent materials in the fields of displays, lighting, sensors and biomarkers. Among the complexes, Cu complexes also exhibit reversible self-recovery photochromic performance. Under UV irradiation, the complexes change from a colorless or light color state to a dark color state rapidly, and after stopping UV irradiation, they gradually return to the light color state.

A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.

The present invention is in relation to the fields of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to improved methods for preparing lipid-conjugated platinum compounds with high purity and good yields. The present disclosure also relates to nanoparticles comprising lipid-conjugated platinum compounds with high drug loading efficiency for use in chemotherapy, and to methods for producing said nanoparticles.

A platinum complex having a structure of Formula (I) particularly of Formula (A) such as Formula (III) or Formula (IIIa). A pharmaceutical composition includes the platinum complex of the present invention and a pharmaceutically acceptable carrier. A method of treating a target tissue includes administering to a patient in need thereof a platinum complex of the present invention and administering to the target tissue radiation in an amount and of a frequency effective to activate the compound. The platinum complex of the present invention can be used in preparation of a medicament for treating the target tissue by sonodynamic therapy, photodynamic therapy, chemotherapy and/or a combination thereof.

A method for treating a proliferative disease, disorder, or condition comprising administering a cis-diamine platinum(II) thione complex. A cis-diamine platinum(II) thione complex and compositions containing it.